Both the chronic nature of SCD, as well as the large amount of intracellular Hb in the blood (millimolar concentrations) that needs to be modified to achieve a therapeutic effect, clearly require potent and long-acting antisickling agents. The gene discussed is GSTM1; the disease is Schnyder corneal dystrophy.